The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.
Huang, R-L., Wang, H. C., & Lai, H-C. (2013). Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine. Biomarkers and Genomic Medicine, 5(3), 125. https://doi.org/10.1016/j.bgm.2013.08.022